Monopar Therapeutics Liquidation Value

Monopar Therapeutics (MNPR) is a pre-revenue clinical-stage biopharmaceutical company with no product sales, no debt, and a balance sheet dominated by liquid financial assets following a large September 2025 equity raise. Under the liquidation lens, the recovery posture is materially positive relative to prior periods and relative to the typical pre-revenue biotech, driven almost entirely by liquid assets that receive near-100% recovery treatment.

As of December 31, 2025, total assets were $140.7M against total liabilities of only $2.9M, yielding reported stockholders equity of $137.8M. Applying liquidation haircuts: cash and cash equivalents of $61.8M recover at 100%; available-for-sale securities (money market funds and U.S. Treasuries) of $60.9M recover at effectively 100% given Level 1 classification and no unrealized loss position; held-to-maturity investments of $78.6M (amortized cost) recover at par given all-U.S. government and high-grade commercial paper holdings with maturities under one year and no credit loss allowance recorded. Total liquid asset base is approximately $201.3M at face/amortized cost against total liabilities of $2.9M, leaving substantial positive recovery to equity under liquidation conditions. The ROU asset ($0.25M) would receive a zero or near-zero haircut in practice as a liability-side operating lease obligation ($0.25M) is the corresponding offset; net impact is neutral.

Compared to the prior filing (10-Q for Q3 2025, period ended September 30, 2025), the primary change is the full-year reflection of the September 2025 equity raise: $126.9M gross proceeds from an underwritten public offering (1,034,433 shares plus 960,542 pre-funded warrants at $67.67 per share/warrant), partially offset by $35.0M used to repurchase 550,229 shares from Tactic Pharma at $63.61 per share, yielding net proceeds of approximately $91.9M before offering expenses. This transaction materially increased the liquid asset base relative to year-end 2024, when total AFS + HTM investments were approximately $60.0M ($45.5M AFS + $14.4M HTM).

The liability stack remains minimal: $2.74M in accounts payable and accrued liabilities plus $0.25M total operating lease liability (current $0.09M, non-current $0.15M). No debt, no pension, no material contingent liabilities that would survive a wind-up. Contingent milestone obligations under the Alexion license ($94M maximum) and XOMA license ($14.9M maximum) are contractually contingent on regulatory and commercial events that have not occurred and would not be triggered in a clean wind-up absent going-concern operations; these are not balance-sheet liabilities and do not affect immediate liquidation recovery.

Full valuation allowance against $22.2M gross deferred tax assets confirms zero incremental recovery from tax assets. Accumulated deficit of $89.5M reflects cumulative operating losses since inception. Net loss for 2025 was $13.7M, down from $15.6M in 2024, primarily reflecting higher interest income ($3.0M vs. not material in 2024) partially offset by higher R&D and G&A spend. The filing discusses unamortized stock-based compensation of $16.4M in MD&A/notes but this is not a balance-sheet liability and does not reduce liquidation value; it will either be forfeited or vest without cash outflow from the company.